Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Study Selenium Health Claim Consumer Perceptions

This article was originally published in The Tan Sheet

Executive Summary

The agency plans to study whether label claim language for selenium misleads consumers on the benefits of the ingredient. Legal experts say with the proposed study, FDA seeks to influence possible regulations down the road and circumvent court rulings that have curbed the agency’s authority to limit supplement claims.

You may also be interested in...



Trade Groups Defend Qualified Health Claims Following Critical GAO Report

Dietary supplement industry stakeholders are defending the use of qualified health claims, which came under fire in a Government Accountability Office report on shortcomings in FDA's food labeling enforcement

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

FDA Details “Quality Agreements” For Marketers, Contract Manufacturers

The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel